PRJ1-3024

N/A

Report date: 2022/08/26 14:15:04
NME

Base Information

Drug NamePRJ1-3024
Drug Alias NamePRJ1-3024
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 1 inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsSolid tumoursMacular DegenerationMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Yinming Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhuhai Yufan Biotechnology Co LtdGuangzhou Yinming Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMacular DegenerationMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A